

81 FR 87978

12/6/2016

<b>As of:</b> 3/28/17 9:02 AM
<b>Received:</b> January 25, 2017
<b>Status:</b> Pending_Post
<b>Tracking No.</b> 1k1-8ud1-f9j2
<b>Comments Due:</b> February 06, 2017
<b>Submission Type:</b> API

# PUBLIC SUBMISSION

8

**Docket:** NRC-2016-0122

Consolidated Guidance About Material Licenses: Program-Specific Guidance About Medical Use Licenses

**Comment On:** NRC-2016-0122-0002

Program-Specific Guidance About Medical Use Licenses; Request for Comments

**Document:** NRC-2016-0122-DRAFT-0004

Comment on FR Doc # 2016-29214

## Submitter Information

**Name:** Caitlin Kubler

**Address:**

1850 Samuel Morse Drive  
Reston, VA, 20190

**Email:** ckubler@snmmi.org

**Submitter's Representative:** Sally Schwarz

**Organization:** Society of Nuclear Medicine and Molecular Imaging

RECEIVED

MAR 28 AM 9:07

RULES 1199 ED/ES


## General Comment

See attached file(s)

## Attachments

SNMMI\_NRC\_radiopharm\_therapy\_FINAL\_2017

SUNSI Review Complete  
 Template = ADM - 013  
 E-RIDS= ADM-03  
 Add= K. Tapp (KNS1)



January 25, 2017

Cindy Bladely  
Office of Administration  
Mail Stop: OWFN-12-H8  
U.S. Nuclear Regulatory Commission  
Washington, DC 20555-0001

Re: Docket ID NRC-2016-0122, Draft Program-Specific Guidance About Medical Use Licenses

Dear Ms. Bladely:

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) would like to provide comments on the draft guidance announced in the Federal Register on December 6, 2016 (81 FR 87978). SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice through the creation of clinical guidelines, sharing evidence-based medicine through journals and meetings, and leading advocacy on key issues that affect molecular imaging and therapy research and practice.

SNMMI has reviewed the comments on Appendix U submitted on Jan. 6, 2017 by Siegel, Stabin, Marcus, and Sacks and supports the scientific contents of the letter. The society is willing to provide our expertise to NRC in order to appropriately revise the draft Appendix U for the benefit of patients, their families, and licensees. Additionally, the society encourages the NRC to consider the more than 20 published articles (see reference list below) dealing with patient release.

As always, SNMMI is ready to discuss any of its comments with the NRC. In this regard, please contact Caitlin Kubler, Senior Manager, Regulatory Affairs, by email at [ckubler@snmmi.org](mailto:ckubler@snmmi.org) or by phone at 703-326-1190.

Sincerely,

Sally Schwarz, MS, RPh, BCNP  
SNMMI President

## REFERENCE LIST

1. Siegel JA. *Nuclear Regulatory Commission Regulation of Nuclear Medicine: Guide for Diagnostic Nuclear Medicine*. Reston, VA: Society of Nuclear Medicine; 2001
2. Siegel JA. *Nuclear Regulatory Commission Regulation of Nuclear Medicine: Guide for Diagnostic Nuclear Medicine and Radiopharmaceutical Therapy*. Reston, VA: Society of Nuclear Medicine; 2004
3. Siegel JA, Marcus CS, and Stabin MG. Licensee over-reliance on conservatism in NRC guidance regarding the release of patients treated with <sup>131</sup>I. *Health Phys* 93:667-677, 2007
4. Siegel JA. Tracking the origin of the NRC 30-mCi rule. *J Nucl Med* 41:10N-16N, 2000
5. Grigsby PW, Siegel BA, Baker S, and Eichling JO. Radiation exposure from outpatient radioactive iodine [<sup>131</sup>I] therapy for thyroid carcinoma. *JAMA* 283:2272-2274, 2000
6. Sparks RB, Siegel JA, and Wahl RL. The need for better methods to determine release criteria for patients administered radioactive material. *Health Phys* 75:385-388, 1998
7. Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: Outpatient Iodine-131 Anti-B1 therapy. *J Nucl Med* 39 (Suppl): 28S-33S, 1998
8. Gates VL, Carey JE, Siegel JA, Kaminski MS, and Wahl RL. Nonmyeloablative Iodine-131 Anti-B1 radioimmunotherapy as outpatient therapy. *J Nucl Med* 39:1230-1236, 1998
9. Siegel JA. Outpatient radionuclide therapy. In, *Radiation Protection in Medicine: Contemporary Issues*, Proceedings of the Thirty-Fifth Annual Meeting of the National Council on Radiation Protection and Measurements, Proceedings No. 21, National Council on Radiation Protection and Measurements, 1999, pp 187-199
10. Siegel JA, Sparks RB, and Wahl RL. An alternative to Monte Carlo in determining release criteria for patients administered radioactive material. Response to Johnson and Barnhart. *Health Phys* 77:726-727, 1999
11. Zanzonico PB, Siegel JA, and Germain JS. A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy. *Health Phys* 78:648-659, 2000
12. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, and Vose JM. Outpatient treatment with <sup>131</sup>I-anti-B1 antibody: Radiation exposure to family members. *J Nucl Med* 42:907-915, 2001
13. Siegel JA and Rutar FJ. Possibility of internal contamination from radionuclide therapy patients released according to 10 CFR 35.75. *RSO Magazine* 6:19-23, 2001

14. Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, and Colcher D. Feasibility and safety of outpatient Bexxar(R) therapy (tositumomab and Iodine I-131 tositumomab) for non-Hodgkin's lymphoma based on the radiation doses to family members. *Clinical Lymphoma* 2:164-172, 2001
15. Siegel JA, Kroll S, Regan D, Kaminski MS, and Wahl RL. A practical methodology for patient release after tositumomab and <sup>131</sup>I-tositumomab therapy. *J Nucl Med* 43:354-363, 2002
16. Siegel JA and Sparks RB. Radioactivity appearing at landfills in household trash of nuclear medicine patients: Much ado about nothing? *Health Phys* 82:367-372, 2002
17. Siegel JA, Marcus CS, and Sparks RB. Calculating the absorbed dose to others from the radioactive patient: Line source model versus point source model. *J Nucl Med* 43:1241-1244, 2002
18. Silberstein EB, Alavi A, Balon HR, Becker DV, Brill DR, Clarke SEM, Divgi C, Goldsmith SJ, Lull RJ, Meier DA, Royal HD, Siegel JA, and Waxman AD. *Society of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide)*. Reston, VA: Society of Nuclear Medicine; 2006
19. Siegel JA, Marcus CS, and Stabin MG. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with <sup>131</sup>I. *Health Phys* 93:667-677, 2007
20. Gulec SA and Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with <sup>90</sup>Y-microspheres. *J Nucl Med* 48:2080-2086, 2007
21. Siegel JA and Marcus CS. Released nuclear medicine patients, security checkpoints, and the NRC. *J Nucl Med* 49:41N-43N, 2008
22. Siegel JA and Silberstein EB. A closer look at the latest NRC patient release guidance. *J Nucl Med* 49:17N-20N, 2008
23. Siegel JA and Stabin MG. Nuclear medicine patient release via the Moses algorithm: let my people go. *Health Physics News XXXVIII* (2):14-17, February 2010
24. Siegel JA and Stabin MG. RADAR response to IAEA position statement on release of radionuclide therapy patients. *Health Physics News XXXVIII* (5):6-7, May 2010
25. de Carvalho AB Jr, Stabin MG, Siegel JA, and Hunt JG. Comparison of point, line and volume dose calculations for exposure to nuclear medicine therapy patients. *Health Phys* 100:185-190, 2011
26. Siegel JA and Silberstein EB. The AEC/NRC 30 mCi rule: regulatory origins and clinical consequences for <sup>131</sup>I remnant ablative dosages. *Thyroid* 24(11):1625-1635, 2014